The Week in Review: September 29 – October 6, 2017

Friday, October 6, 2017 News Recap: Liver Cancer Two studies on liver cancer in the news last week highlighted the global prevalence and causes of this terrible disease.  The first showed a direct correlation between excess weight and cancer occurrence (including liver cancer) – Cancers linked to excess weight make up 40% of all US diagnoses, study finds, while the second focussed on the global incidence of primary liver cancer. Hepatitis B virus wa...

High SVR rates found with AbbVie’s Viekirax and Exviera for hepatitis C – regardless of variants

US pharma major AbbVie (NYSE: ABBV) presented new data on Thursday on patients with genotype 1 chronic hepatitis C virus (HCV) infection who took Viekirax (ombitasvir/paritaprevir/ritonavir) and Exviera (dasabuvir)--Holkira or Viekira Pak. Treated with or without ribavirin (RBV), they achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs). The d...

PATIENT GROUP SUBMISSIONS to BC PharmaCare and CADTH

PATIENT GROUP SUBMISSIONS to BC PharmaCare and CADTH Whenever we are asked to contribute a patient group submission about a hepatitis-C related product, we do so. We contribute as a patient group to reviews by both BC PharmaCare (to determine whether BC PharmaCare patients will be reimbursed for the drugs) and CADTH (federal level – to determine whether the drugs will be available in Canada). Below are the submissions we have made, from the most curre

Information Update – Risk of Serious Liver Injury associated with Hepatitis C Treatments: Holkira Pak and Technivie

OTTAWA, Nov 10, 2015 /CNW/ - In response to new international safety information, Health Canada is advising Canadians that it is working with the manufacturer of Holkira Pak and Technivie to update drug labels (product monographs) to include new information regarding serious liver injury.Holkira Pak and Technivie are both used to treat chronic Hepatitis C viral infection that can lead to serious liver and health problems, including cirrhosis, liver cancer,

FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie

Oct 22, 2015The U.S. Food and Drug Administration (FDA) is warning that hepatitis C treatments Viekira Pak [Holkira Pak in Canada] and Technivie can cause serious liver injury mostly in patients with underlying advanced liver disease. As a result, we are requiring the manufacturer to add new information about this safety risk to the drug labels.Patients taking these medicines should contact their health care professional immediately if they develop fatigue

Aboriginal and Prisoner HCV Drug Coverage for HOLKIRA PAK™

On September 11th we were notified that AbbVie's new interferon-free hepatitis C treatment for genotype 1, HOLKIRA PAK™ (ombitasvir, paritaprevir, ritonovir and dasabuvir [±ribavirin]), is now formally listed by the Non-Insured Health Benefit Program (NIHB) and Correctional Services Canada (CSC). Both have listed HOLKIRA PAK™ in accordance with the Common Drug Review’s recommendations: liver fibrosis stage of ≥2, and treatment should be initiated by physic

Summer of Interferon-free Hepatitis C Drug Approvals?

2015 is stacking up to have a Summer of Interferon-Free hepatitis C drug approvals! So far we've had the following approvals for provincial Pharmacare coverage (addition to provincial "formulary"):On June 29th, Ontario covered AbbVie's Holkira Pak™ for genotype 1, on July 24th, Quebec covered both Gilead's Harvoni™ and AbbVie's Holkira Pak™ for genotype 1. And on World Hepatitis Day, July 28th British Columbia, Saskatchewan, Manitoba, and Yukon started to ...

REQUEST: Patient input for BC Pharmacare RE: HOLKIRA PAK™

BC PharmaCare has issued a call for Patient Input into whether they should cover AbbVie's new hepatitis C treatment, HOLKIRA PAK™ (ombitasvir, paritaprevir, ritonavir, and dasabuvir [±ribavirin]).HepCBC is going to make a submission to BC PharmaCare, and URGENTLY requests input from those who have, or have ever had hepatitis C (and their caregivers). Our submission is only as good as the input we get from people like you!You would have to answer a few ques

REQUEST personal input for Patient Group Submission: HOLKIRA PAK

Do you want new hepatitis C treatment, HOLKIRA PAK™ to be covered by BC PharmaCare? BC PharmaCare has issued a call for Patient Input into whether they should cover AbbVie’s new hepatitis C treatment, HOLKIRA PAK™ (ombitasvir, paritaprevir, ritonavir, and dasabuvir [±ribavirin]). HepCBC is going to make a submission to BC PharmaCare, and URGENTLY requests input from those who have, or have ever had hepatitis C (and their caregivers). Our submission is only